Your browser doesn't support javascript.
loading
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens.
Cytawa, Wojciech; Kircher, Stefan; Kübler, Hubert; Werner, Rudolf A; Weber, Simon; Hartrampf, Philipp; Bandurski, Tomasz; Lass, Piotr; Polom, Wojciech; Matuszewski, Marcin; Wester, Hans-Jürgen; Lapa, Constantin; Rosenwald, Andreas; Seitz, Anna Katharina; Buck, Andreas K.
Afiliação
  • Cytawa W; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany. wcytawa@gumed.edu.pl.
  • Kircher S; Department of Nuclear Medicine, Medical University of Gdansk, Smoluchowskiego Str. 17, 80-952, Gdansk, Poland. wcytawa@gumed.edu.pl.
  • Kübler H; Institute of Pathology, Comprehensive Cancer Center Mainfranken (CCCMF), University of Würzburg, Würzburg, Germany.
  • Werner RA; Department of Urology, University Hospital Würzburg, Würzburg, Germany.
  • Weber S; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
  • Hartrampf P; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
  • Bandurski T; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
  • Lass P; Department of Radiology Informatics and Statistics, Medical University of Gdansk, Gdansk, Poland.
  • Polom W; Department of Nuclear Medicine, Medical University of Gdansk, Smoluchowskiego Str. 17, 80-952, Gdansk, Poland.
  • Matuszewski M; Department of Urology, Medical University of Gdansk, Gdansk, Poland.
  • Wester HJ; Department of Urology, Medical University of Gdansk, Gdansk, Poland.
  • Lapa C; Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany.
  • Rosenwald A; Nuclear Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany.
  • Seitz AK; Institute of Pathology, Comprehensive Cancer Center Mainfranken (CCCMF), University of Würzburg, Würzburg, Germany.
  • Buck AK; Department of Urology, University Hospital Würzburg, Würzburg, Germany.
Eur J Nucl Med Mol Imaging ; 49(11): 3938-3949, 2022 09.
Article em En | MEDLINE | ID: mdl-35556160
PURPOSE: The purpose of this study was to immunohistochemically validate the primary tumor PSMA expression in prostate cancer (PCa) patients imaged with [68Ga]Ga-PSMA PET/CT prior to surgery, with special consideration of PET-negative cases. METHODS: The study included 40 men with newly diagnosed treatment-naïve PCa imaged with [68Ga]Ga-PSMA I&T PET/CT as part of the diagnostic work-up prior to radical prostatectomy. All primary tumors were routinely stained with H&E. In addition, immunohistochemical staining of PSMA was performed and the immunoreactive score (IRS) was computed as semiquantitative measure. Subsequently, imaging findings were correlated to histopathologic results. RESULTS: Eighty-three percent (33/40) of patients presented focal uptake of [68Ga]Ga-PSMA I&T in the primary tumor in at least one prostate lobe. Among PSMA-PET positive patients, one-third had lymph node metastases (LNM) detected by post-operative histopathology, while in PET negative patients, only 1 out of 7 presented with regional LN involvement; PSMA-avid distant lesions, predominantly in bones, were observed in 15% and 0% of patients, respectively. The median IRS classification of PSMA expression in tumor tissue was 2 (range, 1-3) both in PSMA-PET positive and negative prostate lobes, with significantly different interquartile range: 2-3 vs. 2-2, respectively (p = 0.03). The median volume of PSMA-PET positive tumors was 5.4 mL (0.2-32.9) as compared to 1.6 mL (0.3-18.3) of PET-negative tumors (p < 0.001). There was a significant but weak correlation between SUVmax and percentage of PSMA-positive tumor cells (r = 0.46, p < 0.001). A total of 35/44 (~80%) lobes were positive in PSMA-PET imaging, when a cut-off percentage of PSMA-positive cells was ≥ 90%, while 19/36 (~53%) lobes with < 90% PSMA-positive cells were PSMA-PET negative. CONCLUSION: Positive [68Ga]Ga-PSMA I&T PET/CT scan of primary tumor of PCa results from a combination of factors, such as homogeneity and intensity of PSMA expression, tumor volume and grade, with a cutoff value of ≥ 90% PSMA-positive cells strongly determining PET-positivity. Focal accumulation of [68Ga]Ga-PSMA in the primary tumor may correlate positively with aggressiveness of prostate cancer, harboring higher risk of regional LN involvement and distant metastatic spread.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Radioisótopos de Gálio Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Radioisótopos de Gálio Idioma: En Ano de publicação: 2022 Tipo de documento: Article